

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

## EQA round: E22/22 - Hormones 2

Deadline: 03.05.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(393) C-peptide</b>					113							111	111	100%
Samples and groups	[pmol/L]													
<b>Sample A</b>		173	44	25	113							111	111	100%
(3) FIA (FEIA, TRACE); (25) TOSOH		126	4,5	3,6	5	0	CVPG	126	13	20%	100	152	5	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		171	9,5	5,6	34	0	CVPG	172	4,3	20%	137	207	34	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		55,0	7,3	13	7	0	CVPG	55	7,1	20%	44	66	7	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite)		135	6,7	5,0	7	0	CVPG	135	6,5	20%	108	162	7	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		215	9,4	4,4	41	0	CVPG	216	3,5	20%	172	260	41	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		133	7,9	6,0	11	0	CVPG	133	5,9	20%	106	160	11	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		131	4,4	3,4	6	0	CVPG	140	14	20%	112	168	6	
Other					2	0							0	
								1x 1/36, 1x 4/164						
<b>Sample B</b>		375	88	24	113							111	111	100%
(3) FIA (FEIA, TRACE); (25) TOSOH		310	3,9	1,2	5	0	CVPG	310	11	20%	248	372	5	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		375	17	4,5	34	0	CVPG	376	7,7	20%	300	452	34	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		244	20	8,2	7	0	CVPG	244	19	20%	195	293	7	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite)		317	12	3,8	7	0	CVPG	317	12	20%	253	381	7	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		458	16	3,5	41	0	CVPG	459	5,9	20%	367	551	41	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		261	16	6,1	11	0	CVPG	261	12	20%	208	314	11	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		270	5,6	2,1	6	0	CVPG	269	5,0	20%	215	323	6	
Other					2	0							0	
								1x 1/36, 1x 4/164						
<b>(193) Ferritin</b>					122							118	117	99%
Samples and groups	[µg/L]													
<b>Sample A</b>		43,3	9,8	23	122							118	117	99%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		41,9	3,7	8,9	39	0	CVPG	43,4	0,90	±16,8	26,6	60,2	39	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		32,0	1,5	4,6	5	0	CVPG	32,2	1,1	±16,8	15,4	49	5	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		50,1	3,4	6,7	31	0	CVPG	52,5	0,61	±16,8	35,7	69,3	31	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		29,3	3,5	12	13	0	CVPG	31,8	1,2	±16,8	15	48,6	13	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		33,1	4,3	13	9	0	CVPG	34,1	1,3	±16,8	17,3	50,9	9	
(6) IMT, IMN; (60) Roche		54,7	3,4	6,2	12	0	CVPG	56,8	1,3	±16,8	40	73,6	12	
Other					13	0							9	
								1x 3/25, 1x 4/29, 1x 4/40, 1x 4/149, 3x 6/1, 1x 6/5, 4x 6/58, 1x 6/999						
<b>Sample B</b>		222	40	18	122							118	118	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		246	22	9,0	39	0	CVPG	254	4,8	24%	193	315	39	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		166	3,0	1,8	5	0	CVPG	168	4,8	24%	127	209	5	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		242	19	8,0	31	0	CVPG	249	2,7	24%	189	309	31	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		164	14	8,2	13	0	CVPG	167	5,4	24%	126	208	13	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		180	14	7,9	9	0	CVPG	178	7,9	24%	135	221	9	
(6) IMT, IMN; (60) Roche		230	17	7,3	12	0	CVPG	243	4,4	24%	184	302	12	
Other					13	0							9	
								1x 3/25, 1x 4/29, 1x 4/40, 1x 4/149, 3x 6/1, 1x 6/5, 4x 6/58, 1x 6/999						
<b>(321) FSH</b>					103							101	95	94%
Samples and groups	[U/L]													
<b>Sample A</b>		15,6	1,6	10	103							101	97	96%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		14,6	0,68	4,6	33	0	CVPG	14,8	0,14	15%	12,5	17,1	33	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		17,0	1,0	5,9	12	0	CVPG	16,7	0,24	15%	14,1	19,3	12	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		15,2	0,85	5,6	29	0	CVPG	15,1	0,090	15%	12,8	17,4	29	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		17,5	0,46	2,6	13	0	CVPG	17,3	0,35	15%	14,7	19,9	13	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		16,4	1,1	6,8	7	0	CVPG	16,6	0,30	15%	14,1	19,1	7	

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

## EQA round: E22/22 - Hormones 2

Deadline: 03.05.2022

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(321) FSH</b>					103							101	95	94%
--- Samples and groups	[U/L]													
<b>Sample A</b>		15,6	1,6	10	103							101	97	96%
Other					9	0						7		
							4x 3/25, 2x 4/29, 1x 4/40, 1x 4/149, 1x 4/164							
<b>Sample B</b>		4,79	0,44	9,1	103							101	96	95%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		4,54	0,27	6,0	33	0	CVPG	4,57	0,055	15%	3,88	5,26	33	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		5,42	0,54	10	12	0	CVPG	5,41	0,080	15%	4,59	6,23	12	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		4,85	0,32	6,6	29	0	CVPG	4,86	0,028	15%	4,13	5,59	29	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		4,67	0,34	7,3	13	0	CVPG	4,71	0,12	15%	4	5,42	13	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		4,79	0,42	8,8	7	0	CVPG	4,92	0,12	15%	4,18	5,66	7	
Other					9	0						7		
							4x 3/25, 2x 4/29, 1x 4/40, 1x 4/149, 1x 4/164							
<b>(328) hGH</b>					24							21	19	90%
--- Samples and groups	[mU/L]													
<b>Sample A</b>		5,16	0,96	19	24							21	21	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin)		5,44	0,24	4,4	6	0	CVPG	5,62	0,11	±1,54	4,08	7,16	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		5,83	0,26	4,5	7	0	CVPG	6,01	0,098	±1,54	4,47	7,55	7	
Other					11	0						8		
							2x 1/36, 1x 3/25, 2x 4/12, 1x 4/162, 2x 4/164, 2x 4/183, 1x 4/999							
<b>Sample B</b>		13,7	1,3	9,6	24							21	19	90%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin)		13,9	0,57	4,1	6	0	CVPG	14,8	0,30	19%	11,9	17,7	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		14,4	0,99	6,8	7	0	CVPG	15,4	0,23	19%	12,4	18,4	7	
Other					11	0						8		
							2x 1/36, 1x 3/25, 2x 4/12, 1x 4/162, 2x 4/164, 2x 4/183, 1x 4/999							
<b>(329) IGF-1</b>					25							24	24	100%
--- Samples and groups	[µg/L]													
<b>Sample A</b>		123	32	26	25							24	24	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin)		149	12	8,0	6	0	CVPG	146	2,6	22%	113	179	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		93,4	5,1	5,4	9	0	CVPG	91,1	1,2	22%	71	112	9	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin		146	5,3	3,7	6	0	CVPG	139	3,3	22%	108	170	6	
Other					4	0						3		
							3x 4/183, 1x 4/999							
<b>Sample B</b>		158	29	18	25							24	24	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin)		145	7,4	5,1	6	0	CVPG	144	3,1	22%	112	176	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		140	7,6	5,4	9	0	CVPG	139	1,7	22%	108	170	9	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin		204	13	6,2	6	0	CVPG	198	4,1	22%	154	242	6	
Other					4	0						3		
							3x 4/183, 1x 4/999							
<b>(392) IGF-BP3</b>					8							6	6	100%
--- Samples and groups	[µg/L]													
<b>Sample A</b>		3640	560	15	8							6	6	100%
Other					8	0						6		
							1x 1/36, 2x 4/29, 3x 4/60, 1x 4/183, 1x 4/999							
<b>Sample B</b>		3500	750	21	8							6	6	100%
Other					8	0						6		
							1x 1/36, 2x 4/29, 3x 4/60, 1x 4/183, 1x 4/999							
<b>(325) Insulin</b>					29							27	27	100%
--- Samples and groups	[mU/L]													
<b>Sample A</b>		49,1	6,0	12	29							27	27	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		41,8	4,1	9,8	7	0	CVPG	40,5	1,3	20%	32,4	48,6	7	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		53,8	2,7	5,1	10	0	CVPG	53,7	0,51	20%	42,9	64,5	10	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		49,7	3,8	7,6	5	0	CVPG	49,7	1,8	20%	39,7	59,7	5	
Other					7	0						5		
							1x 1/36, 1x 3/25, 3x 4/12, 2x 4/179							
<b>Sample B</b>		9,90	1,6	16	29							27	27	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		8,00	0,15	1,9	7	0	CVPG	8,04	0,25	20%	6,43	9,65	7	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		11,2	0,76	6,8	10	0	CVPG	11,1	0,11	20%	8,88	13,4	10	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		10,0	0,64	6,4	5	0	CVPG	10	0,32	20%	8	12	5	
Other					7	0						5		
							1x 1/36, 1x 3/25, 3x 4/12, 2x 4/179							

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

## EQA round: E22/22 - Hormones 2

Deadline: 03.05.2022

Test	[unit]						Comparability							N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>		
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL							
<b>(326) Folate</b>					130										0			
Samples and groups	[nmol/L]																	
<b>Sample A</b>		60,3	19	32	130										0			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		69,6	20	28	45	1	CVPG	67	4,4	27%	48,9	85,1			0			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		54,7	6,7	12	10	0	CVPG	56,8	2,9	27%	41,4	72,2			0			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		45,8	0,97	2,1	52	0	CVPG	50,5	1,2	27%	36,8	64,2			0			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		72,7	29	40	11	0	CVPG	79,6	11	27%	58,1	102			0			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		54,4	0,000	0,00	9	0	CVPG	75,1	13	27%	54,8	95,4			0			
Other					3	0									0			
								1x 3/25, 1x 4/29, 1x 4/149										
<b>Sample B</b>		22,8	3,7	16	130										129	123	95%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		25,3	2,0	7,8	45	0	CVPG	25,6	0,43	27%	18,6	32,6			45			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		26,3	2,9	11	10	0	CVPG	25,9	0,66	27%	18,9	32,9			10			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		20,0	2,1	10	52	0	CVPG	19,4	0,21	27%	14,1	24,7			52			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		23,3	1,6	6,8	11	0	CVPG	22,9	0,85	27%	16,7	29,1			11			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		22,1	1,7	7,6	9	0	CVPG	23,2	0,98	27%	16,9	29,5			9			
Other					3	0									2			
								1x 3/25, 1x 4/29, 1x 4/149										
<b>(320) LH</b>					99										97	96	99%	
Samples and groups	[U/L]																	
<b>Sample A</b>		7,80	2,0	25	99										97	96	99%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		5,93	0,29	4,8	32	0	CVPG	6,01	0,069	15%	5,1	6,92			32			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		7,56	0,58	7,7	10	0	CVPG	7,68	0,16	15%	6,52	8,84			10			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		10,1	0,40	3,9	29	0	CVPG	10,0	0,060	15%	8,5	11,5			29			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		7,51	0,32	4,3	13	0	CVPG	7,37	0,10	15%	6,26	8,48			13			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		7,39	0,55	7,4	6	0	CVPG	7,44	0,15	15%	6,32	8,56			6			
Other					9	0									7			
								4x 3/25, 2x 4/29, 1x 4/40, 1x 4/149, 1x 4/164										
<b>Sample B</b>		10,4	2,3	22	99										97	97	100%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		8,46	0,42	4,9	32	0	CVPG	8,59	0,095	15%	7,3	9,88			32			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		8,49	0,64	7,5	10	0	CVPG	8,75	0,20	15%	7,43	10,1			10			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		12,8	0,48	3,8	29	0	CVPG	12,7	0,077	15%	10,7	14,7			29			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		10,5	0,54	5,1	13	0	CVPG	10,1	0,17	15%	8,58	11,7			13			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		9,89	0,93	9,4	6	0	CVPG	10,3	0,30	15%	8,75	11,9			6			
Other					9	0									7			
								4x 3/25, 2x 4/29, 1x 4/40, 1x 4/149, 1x 4/164										
<b>(407) Parathyroid hormone (PTH 1-84)</b>					32										32	28	88%	
Samples and groups	[pmol/L]																	
<b>Sample A</b>		3,65	0,60	17	32										32	28	88%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		3,80	0,44	12	28	0	CVPG	3,8	0,18	17%	3,15	4,45			28			
Other					4	0									4			
								4x 4/164										
<b>Sample B</b>		5,86	0,67	12	32										32	32	100%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		6,00	0,52	8,7	28	0	CVPG	6	0,20	17%	4,98	7,02			28			
Other					4	0									4			
								4x 4/164										
<b>(405) Parathyroid hormone (PTH)</b>					53										50	46	92%	
Samples and groups	[pmol/L]																	
<b>Sample A</b>		3,85	1,1	27	53										50	46	92%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		5,47	0,53	9,7	12	0	CVPG	5,33	0,19	23%	4,1	6,56			12			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		3,01	0,31	10	5	0	CVPG	3,14	0,24	23%	2,41	3,87			5			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		3,21	0,17	5,3	21	0	CVPG	3,08	0,044	23%	2,37	3,79			21			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		4,22	0,69	16	7	0	CVPG	4,09	0,27	23%	3,14	5,04			7			
Other					8	0									5			
								1x 2/999, 1x 3/25, 1x 4/29, 4x 4/179, 1x 4/999										
<b>Sample B</b>		6,69	1,5	22	53										50	49	98%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		9,00	0,90	10	12	0	CVPG	8,89	0,18	23%	6,84	11			12			

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

## EQA round: E22/22 - Hormones 2

Deadline: 03.05.2022

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(405) Parathyroid hormone (PTH)</b>					53							50	46	92%
Samples and groups	[pmol/L]													
<b>Sample B</b>		6,69	1,5	22	53							50	49	98%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		6,66	0,39	5,8	5	0	CVPG	6,84	0,27	23%	5,26	8,42		5
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		5,58	0,29	5,2	21	0	CVPG	5,4	0,054	23%	4,15	6,65		21
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		6,72	0,77	11	7	0	CVPG	6,44	0,20	23%	4,95	7,93		7
Other					8	0								5
								1x 2/999, 1x 3/25, 1x 4/29, 4x 4/179, 1x 4/999						
<b>(322) Prolactin</b>					108							106	102	96%
Samples and groups	[mU/L]													
<b>Sample A</b>		379	70	19	108							106	102	96%
(3) FIA (FEIA, TRACE); (25) TOSOH		316	39	12	5	0	CVPG	327	57	16%	274	380		5
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		389	24	6,3	34	0	CVPG	393	5,7	16%	330	456		34
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		348	29	8,3	11	0	CVPG	354	8,1	16%	297	411		11
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		448	23	5,2	33	0	CVPG	438	3,1	16%	367	509		33
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		292	20	6,7	12	0	CVPG	289	5,8	16%	242	336		12
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		280	30	11	7	0	CVPG	282	7,5	16%	236	328		7
Other					6	0								4
								3x 4/29, 1x 4/40, 1x 4/149, 1x 4/164						
<b>Sample B</b>		230	39	17	108							106	104	98%
(3) FIA (FEIA, TRACE); (25) TOSOH		192	21	11	5	0	CVPG	196	30	16%	164	228		5
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		238	16	6,9	34	0	CVPG	241	3,5	16%	202	280		34
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		208	18	8,5	11	0	CVPG	213	4,8	16%	178	248		11
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		267	14	5,4	33	0	CVPG	261	1,7	16%	219	303		33
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		182	7,5	4,1	12	0	CVPG	182	2,4	16%	152	212		12
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		177	9,9	5,6	7	0	CVPG	178	2,9	16%	149	207		7
Other					6	0								4
								3x 4/29, 1x 4/40, 1x 4/149, 1x 4/164						
<b>(390) Renin</b>					20							20	17	85%
Samples and groups	[ng/L]													
<b>Sample A</b>		64,6	8,9	14	20							20	18	90%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin		59,6	3,0	5,1	9	0	CVPG	57,8	0,81	20%	46,2	69,4		9
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (183) Immunodiagnostic Systems		72,8	4,3	5,9	7	0	CVPG	72,5	1,8	20%	58	87		7
Other					4	0								4
								3x 1/36, 1x 2/66						
<b>Sample B</b>		45,9	6,4	14	20							20	18	90%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin		45,4	3,2	7,1	9	0	CVPG	44,5	0,76	20%	35,6	53,4		9
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (183) Immunodiagnostic Systems		50,7	1,9	3,8	7	0	CVPG	50,8	1,2	20%	40,6	61		7
Other					4	0								4
								3x 1/36, 1x 2/66						
<b>(394) SHBG</b>					58							56	54	96%
Samples and groups	[nmol/L]													
<b>Sample A</b>		62,2	5,2	8,4	58							56	54	96%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		62,6	4,0	6,3	18	0	CVPG	62,7	1,1	20%	50,1	75,3		18
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		61,2	4,7	7,6	5	0	CVPG	60,8	1,9	20%	48,6	73		5
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		64,4	4,2	6,5	21	0	CVPG	62,9	0,49	20%	50,3	75,5		21
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		58,2	5,9	10	6	0	CVPG	60,2	2,1	20%	48,1	72,3		6
Other					8	0								6
								1x 1/36, 3x 4/29, 3x 4/179, 1x 4/999						
<b>Sample B</b>		33,6	2,3	7,0	58							56	56	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		34,1	2,7	7,8	18	0	CVPG	34,1	0,74	20%	27,2	41		18
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		32,0	0,300	0,93	5	0	CVPG	32,8	1,1	20%	26,2	39,4		5
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		33,4	1,8	5,3	21	0	CVPG	32,6	0,24	20%	26	39,2		21
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		32,8	2,7	8,1	6	0	CVPG	33,5	0,92	20%	26,8	40,2		6
Other					8	0								6
								1x 1/36, 3x 4/29, 3x 4/179, 1x 4/999						

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

## EQA round: E22/22 - Hormones 2

Deadline: 03.05.2022

Test	[unit]							Comparability						
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(327) Vitamin B12</b>					109							108	103	95%
Samples and groups	[pmol/L]													
<b>Sample A</b>		1100	88	8,0	109							108	104	96%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		1130	97	8,6	36	0	CVPG	1130	18	20%	904	1360		36
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		936	67	7,1	11	0	CVPG	909	21	20%	727	1100		11
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		1100	46	4,2	45	0	CVPG	1070	6,1	20%	856	1290		45
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		1140	170	15	8	0	CVPG	1140	46	20%	912	1370		8
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		1280	300	23	6	0	CVPG	1300	68	20%	1040	1560		6
Other					3	0								2
								1x 3/25, 1x 4/29, 1x 4/149						
<b>Sample B</b>		268	38	14	109							108	106	98%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		252	20	7,9	36	0	CVPG	256	4,2	20%	204	308		36
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		190	12	6,5	11	0	CVPG	186	4,0	20%	148	224		11
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		297	22	7,5	45	0	CVPG	283	2,5	20%	226	340		45
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		272	27	9,8	8	0	CVPG	265	11	20%	212	318		8
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		259	30	12	6	0	CVPG	255	11	20%	204	306		6
Other					3	0								2
								1x 3/25, 1x 4/29, 1x 4/149						
<b>(319) Vitamin B12 (active)</b>					35									0
Samples and groups	[pmol/L]													
<b>Sample A</b>		214	79	37	35									0
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		216	69	32	19	0	CVPG	215	36	20%	172	258		0
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		291	210	72	7	0	CVPG	291	260	20%	232	350		0
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		218	110	49	5	0	CVPG	218	300	20%	174	262		0
Other					4	1								0
								4x 4/179						
<b>Sample B</b>		82,8	6,0	7,3	35									31
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		84,7	6,2	7,3	19	0	CVPG	85,3	3,3	20%	68,2	103		19
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		76,1	4,5	5,9	7	0	CVPG	75,6	4,8	20%	60,4	90,8		7
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		85,8	2,3	2,7	5	0	CVPG	85,8	6,6	20%	68,6	103		5
Other					4	0								0
								4x 4/179						

st\_kn\_p

End of report

Printed: 16.05.2022